TY - JOUR
T1 - Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
AU - Jonker, Derek J
AU - Karapetis, Chris
AU - Harbison, Christopher T
AU - O'Callaghan, Chris J
AU - Tu, Dongsheng
AU - Simes, R John
AU - Malone, Daniel P
AU - Langer, Christiane
AU - Tebbutt, Niall
AU - Price, Timothy J
AU - Shapiro, Jeremy
AU - Siu, Lillian L
AU - Wong, Ralph P W
AU - Bjarnason, Georg A
AU - Moore, Malcolm J
AU - Zalcberg, John Raymond
AU - Khambata-Ford, Shirin
PY - 2014
Y1 - 2014
N2 - Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit.Methods:Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS) were examined for treatment-biomarker interaction.Results:Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and K-ras wild-type status ( co-biomarker )-positive group (n=139, 36 ), median PFS was 5.4 vs 1.9 months (hazard ratio (HR) 0.31; P
AB - Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit.Methods:Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS) were examined for treatment-biomarker interaction.Results:Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and K-ras wild-type status ( co-biomarker )-positive group (n=139, 36 ), median PFS was 5.4 vs 1.9 months (hazard ratio (HR) 0.31; P
UR - http://www.nature.com/bjc/journal/v110/n3/full/bjc2013753a.html
U2 - 10.1038/bjc.2013.753
DO - 10.1038/bjc.2013.753
M3 - Article
VL - 110
SP - 648
EP - 655
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 3
ER -
